Evidence map›Paper›PMID 22940027›Full record

Trial reportThe Lancet. Infectious diseases2012

Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study.

Chanaki Amaratunga, Sokunthea Sreng, Seila Suon, Erika S Phelps, Kasia Stepniewska, Pharath Lim, Chongjun Zhou, Sivanna Mao, Jennifer M Anderson, Niklas Lindegardh and 10 more

2 registry-linked trialsOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in The Lancet. Infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 223 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
223citing papers in PubMed, 4 pooled it
38.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00341003 completednot on this map

Multidisciplinary Studies of Severe Malaria and Antimalarial Drug Resistance in Cambodia

TypeobservationalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2005 to 2011Enrolled2,090ConditionsSevere Malaria, Malaria, Antimalarial Drug Resistance
NCT01872702 nacompletednot on this mapstarted 2013, after this paper: background citation

Targeted Chemo-elimination (TCE) to Eradicate Malaria in Areas of Suspected or Proven Artemisinin Resistance in Southeast Asia and South Asia

TypeinterventionalSponsorUniversity of OxfordRan2013 to 2017Enrolled8,000ConditionsPlasmodium Falciparum MalariaArmsmalaria elimination using DP and low-dose primaquine
3 · Its place in the literature

Who cites it

223 citing papers in PubMed, 4 syntheses or guidelines pooled it, 352 citations in OpenAlex.

  1. Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

163 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 5 countries.

Chanaki AmaratungaLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.
Sokunthea Sreng
Seila Suon
Erika S Phelps
Kasia Stepniewska
Pharath Lim
Chongjun Zhou
Sivanna Mao
Jennifer M Anderson
Niklas Lindegardh
Hongying Jiang
Jianping Song
Xin-zhuan Su
Nicholas J White
Arjen M Dondorp
Tim J C Anderson
Michael P Fay
Jianbing Mu
Socheat Duong
Rick M Fairhurst
National Institutes of Health · USCambodia National Malaria Center · KHNational Institute of Allergy and Infectious Diseases · USGuangzhou University · CNMahidol University · THInfectious Diseases Data Observatory · GBMahidol Oxford Tropical Medicine Research Unit · THTexas Biomedical Research Institute · US

Funding

Malaria Parasite Sexual Development, Drug Resistance, and EvolutionZIAAI000892 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SU, XINZHUAN · 2009 to 2025
$23.3M
Malaria Pathogenesis and Human ImmunityZIAAI001000 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FAIRHURST, RICK · 2009 to 2017
$9.3M
Mapping Drug Resistance Genes in Plasmodium falciparumR37AI048071 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J · 2012 to 2021
$7.9M
Intramural NIH HHS ZIA AI001000NIAID NIH HHS R37 AI048071Wellcome Trust 089275Wellcome Trust 093956
6 · The paper itself

Abstract

backgroundArtemisinin-resistant Plasmodium falciparum has been reported in Pailin, western Cambodia, detected as a slow parasite clearance rate in vivo. Emergence of this phenotype in western Thailand and possibly elsewhere threatens to compromise the effectiveness of all artemisinin-based combination therapies. Parasite genetics is associated with parasite clearance rate but does not account for all variation. We investigated contributions of both parasite genetics and host factors to the artemisinin-resistance phenotype in Pursat, western Cambodia.

methodsBetween June 19 and Nov 28, 2009, and June 26 and Dec 6, 2010, we enrolled patients aged 10 years or older with uncomplicated falciparum malaria, a density of asexual parasites of at least 10,000 per μL of whole blood, no symptoms or signs of severe malaria, no other cause of febrile illness, and no chronic illness. We gave participants 4 mg/kg artesunate at 0, 24, and 48 h, 15 mg/kg mefloquine at 72 h, and 10 mg/kg mefloquine at 96 h. We assessed parasite density on thick blood films every 6 h until undetectable. The parasite clearance half-life was calculated from the parasite clearance curve. We genotyped parasites with 18 microsatellite markers and patients for haemoglobin E, α-thalassaemia, and a mutation of G6PD, which encodes glucose-6-phosphate dehydrogenase. To account for the possible effects of acquired immunity on half-life, we used three surrogates for increased likelihood of exposure to P falciparum: age, sex, and place of residence. This study is registered with ClinicalTrials.gov, number NCT00341003.

findingsWe assessed 3504 individuals from all six districts of Pursat province seeking treatment for malaria symptoms. We enrolled 168 patients with falciparum malaria who met inclusion criteria. The geometric mean half-life was 5·85 h (95% CI 5·54-6·18) in Pursat, similar to that reported in Pailin (p=0·109). We identified two genetically different parasite clone groups: parasite group 1 (PG1) and parasite group 2 (PG2). Non-significant increases in parasite clearance half-life were seen in patients with haemoglobin E (0·55 h; p=0·078), those of male sex (0·96 h; p=0·064), and in 2010 (0·68 h; p=0·068); PG1 was associated with a significant increase (0·79 h; p=0·033). The mean parasite heritability of half-life was 0·40 (SD 0·17).

interpretationHeritable artemisinin resistance is established in a second Cambodian province. To accurately identify parasites that are intrinsically susceptible or resistant to artemisinins, future studies should explore the effect of erythrocyte polymorphisms and specific immune responses on half-life variation.

fundingDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Indexed as

Drug ResistanceAdolescentAdultAnimalsAntimalarialsArtemisininsCambodiaFemaleGenotypeGlucosephosphate DehydrogenaseHumansMalaria, FalciparumMaleMefloquineMicrosatellite RepeatsPlasmodium falciparumAntimalarialsartemisininArtemisininsGlucosephosphate DehydrogenaseMefloquine

Identifiers

PMID22940027
PMCPMC3786328
OpenAlexW2139324809

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.